Profile data is unavailable for this security.
About the company
Beijing Konruns Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development, production and sales of drugs. The Company's main product Suling belongs to the haemocoagulase drug that activates the coagulation process, which is primarily used to prevent and treat perioperative exudate. Its product Miacalcic, is salmon calcitonin, a peptide drug primarily used to regulate calcium metabolism and inhibit osteoclast activity. The Company's products under research include KC1036 for oncology, the analgesic ZY5301, the innovative drug KC1086, and a Pit Viper hemocoagulase injectable for dogs. The Company mainly distributes its products in the domestic market.
- Revenue in CNY (TTM)871.31m
- Net income in CNY57.12m
- Incorporated2003
- Employees668.00
- LocationBeijing Konruns Pharmaceutical Co LtdNo. 3 Building, No. 7 YardKexueyuan Road, Zhongguancun LifeScience Park, Changping DistrictBEIJING 102206ChinaCHN
- Phone+86 1 082898898
- Fax+86 1 082898886
- Websitehttps://www.konruns.cn/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ChengDu Sheng Nuo Biotec Co Ltd | 638.35m | 120.09m | 6.08bn | 1.38k | 50.77 | 5.90 | -- | 9.53 | 0.7615 | 0.7615 | 4.09 | 6.56 | 0.3714 | 0.973 | 4.28 | 462,238.30 | 6.98 | 6.05 | 10.10 | 7.75 | 55.34 | 66.00 | 18.80 | 14.91 | 0.9008 | 14.11 | 0.3862 | 26.83 | 4.84 | 6.90 | -28.88 | 0.7741 | 51.66 | -- |
| Beijing Konruns Pharmaceutical Co Ltd | 871.31m | 57.12m | 6.70bn | 668.00 | 119.92 | 2.10 | -- | 7.69 | 0.3515 | 0.3515 | 5.55 | 20.06 | 0.2166 | 1.58 | 2.86 | 1,304,353.00 | 0.8033 | 3.82 | 0.9658 | 4.45 | 89.11 | 88.68 | 3.71 | 16.16 | 2.98 | -- | 0.0745 | 31.72 | -10.28 | -4.99 | -71.94 | -30.80 | 40.67 | -- |
| Shanghai OPM Biosciences Co Ltd | 352.91m | 43.24m | 6.85bn | 328.00 | 140.33 | 2.84 | -- | 19.40 | 0.3751 | 0.3751 | 3.18 | 18.51 | 0.1558 | 2.50 | 4.05 | 1,075,953.00 | 1.88 | 3.50 | 1.96 | 3.69 | 50.40 | 57.44 | 12.09 | 21.40 | 15.47 | -- | 0.0272 | 58.30 | 22.26 | 38.41 | -61.04 | -- | 43.46 | -- |
| Shanghai Fudan-Zhangjiang Bio-Pharm. Co | 711.63m | -62.67m | 7.07bn | 925.00 | -- | 3.96 | -- | 9.94 | -0.0605 | -0.0605 | 0.6865 | 2.18 | 0.2795 | 2.02 | 2.18 | 769,331.60 | -2.47 | 5.01 | -2.70 | 6.20 | 88.90 | 91.92 | -8.83 | 14.50 | 8.51 | -11.45 | 0.007 | 48.29 | -16.61 | -7.17 | -63.42 | -29.45 | 1.11 | -- |
| Shanghai Haixin Group Co Ltd | 788.05m | 156.25m | 7.08bn | 715.00 | 64.45 | 2.16 | -- | 8.98 | 0.1294 | 0.1294 | 0.6529 | 3.87 | 0.1404 | 5.99 | 8.40 | 1,102,168.00 | 3.13 | 2.89 | 3.42 | 3.27 | 51.52 | 46.43 | 22.33 | 12.82 | 4.42 | -- | 0.0209 | 35.43 | -32.70 | -6.47 | -9.09 | 7.75 | -34.08 | 5.92 |
Data as of Feb 13 2026. Currency figures normalised to Beijing Konruns Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
7.14%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| China Universal Asset Management Co., Ltd.as of 30 Jun 2025 | 1.43m | 0.91% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2025 | 1.39m | 0.88% |
| E Fund Management Co., Ltd.as of 30 Jun 2025 | 1.34m | 0.85% |
| China Fund Management Co., Ltd.as of 30 Jun 2025 | 1.25m | 0.79% |
| Huatai-PineBridge Fund Management Co., Ltd.as of 30 Jun 2025 | 1.15m | 0.73% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2025 | 1.03m | 0.66% |
| Wanjia Asset Management Co., Ltd.as of 30 Jun 2025 | 1.02m | 0.65% |
| ABC-CA Fund Management Co., Ltd.as of 30 Jun 2025 | 1.02m | 0.65% |
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2025 | 896.16k | 0.57% |
| Cinda Fund Management Co. Ltd.as of 30 Jun 2025 | 730.90k | 0.46% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
